Abstract
The current use of antineoplastic drugs in human therapy causes a substancial number of toxic or side effects which consequently lead to a reduction of the amount of drug to be administered, and in some cases to discontinuation of the therapy. A reduction of the amount of drug to be administered or discontinuation of the therapy causes an increase in primary tumour growth and/or the occurrence of tumour metastases. For this reason, the development of new anti-cancer drugs with lower side effects is necessary. This review gives a general idea about the origins of cancer and the importance of cyclooxygenase-2 (COX-2) in oncogenesis. Evidence from clinical and preclinical studies indicates that COX-2 – derived prostaglandins participate in carcinogenesis, inflammation, immune response suppression, apoptosis inhibition, angiogenesis, and tumour cell invasion and metastasis. The recent anti-tumour drugs are based on tests of known selective COX-2 inhibitors and on the drawing and synthesis of new potent derivatives. Maybe, this can be the way to obtain new anti-tumour drugs with very low collateral effects. Selective COX-2 inhibitors are being mixtured with new anti-cancer drugs in order to obtain better results in the regression of cancers. Some natural products are selective COX-2 inhibitors and have anti-inflammatory and anti-cancer properties. The relevant patents are discussed.
Keywords: Cyclooxygenase, tumour, melatonin, sumatriptan, omega 6, magnesium, indomethacin, selective COX-2 inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Selective Cyclooxygenase-2 (COX-2) Inhibitors Used for Preventing or Regressing Cancer
Volume: 4 Issue: 2
Author(s): Ricardo de Souza Pereira
Affiliation:
Keywords: Cyclooxygenase, tumour, melatonin, sumatriptan, omega 6, magnesium, indomethacin, selective COX-2 inhibitors
Abstract: The current use of antineoplastic drugs in human therapy causes a substancial number of toxic or side effects which consequently lead to a reduction of the amount of drug to be administered, and in some cases to discontinuation of the therapy. A reduction of the amount of drug to be administered or discontinuation of the therapy causes an increase in primary tumour growth and/or the occurrence of tumour metastases. For this reason, the development of new anti-cancer drugs with lower side effects is necessary. This review gives a general idea about the origins of cancer and the importance of cyclooxygenase-2 (COX-2) in oncogenesis. Evidence from clinical and preclinical studies indicates that COX-2 – derived prostaglandins participate in carcinogenesis, inflammation, immune response suppression, apoptosis inhibition, angiogenesis, and tumour cell invasion and metastasis. The recent anti-tumour drugs are based on tests of known selective COX-2 inhibitors and on the drawing and synthesis of new potent derivatives. Maybe, this can be the way to obtain new anti-tumour drugs with very low collateral effects. Selective COX-2 inhibitors are being mixtured with new anti-cancer drugs in order to obtain better results in the regression of cancers. Some natural products are selective COX-2 inhibitors and have anti-inflammatory and anti-cancer properties. The relevant patents are discussed.
Export Options
About this article
Cite this article as:
Pereira de Souza Ricardo, Selective Cyclooxygenase-2 (COX-2) Inhibitors Used for Preventing or Regressing Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452849
DOI https://dx.doi.org/10.2174/157489209788452849 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Autophagy Inhibits Apoptosis Induced by agrocybe aegerita Lectin in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis, <i>In Silico</i> and <i>In Vivo</i> Evaluation of Novel 1, 3, 4-Thiadiazole Analogues as Novel Anticancer Agents
Letters in Drug Design & Discovery Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Despite an Extensive Sequence Analysis Identification of Functional Candidates Amongst Hypothetical Proteins of Neisseria gonorrhoeae
Letters in Drug Design & Discovery TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth
Current Medicinal Chemistry A High Throughput Scintillation Proximity Imaging Assay for Protein Methyltransferases
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Potential Therapeutic Agents based on DNA Sequence- Selective Binding Substances)
Current Topics in Medicinal Chemistry Subject index to volume 3
Current Molecular Medicine Tumor Physiology and Delivery of Nanopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Isolation of Antibodies From Non-Human Primates for Clinical Use
Current Drug Discovery Technologies Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway
Current Cancer Drug Targets Benzofuran: A Key Heterocycle - Ring Closure And Beyond
Mini-Reviews in Organic Chemistry Synthesis, Characterization and Anti-hepatoma Activity of New Hederagenin Derivatives
Mini-Reviews in Medicinal Chemistry